Literature DB >> 30374275

Detecting Novel Urine Biomarkers for the Early Diagnosis of Prostate Cancer: Platelet Derived Growth Factor-BB as a Possible New Target.

Athanasios Skarmoutsos1, Ioannis Skarmoutsos1, Ioannis Katafigiotis1,2, Elisavet Tataki1, Athina Giagini3, Christos Alamanis1, Ioannis Anastasiou1, Anastasios Angelou1, Mordechai Duvdevani2, Nikolaos Sitaras3, Constantinos Constantinides1.   

Abstract

INTRODUCTION: Although the prostate specific antigen revolutionized the diagnosis of prostate cancer (PCa), it has its limitations. We prospectively examined the potential use of the platelet-derived growth factor-BB (PDGF-BB) as a urine biomarker for the early diagnosis of PCa.
MATERIALS AND METHODS: The urine samples of 118 patients were collected after a prostatic massage and all the patients subsequently underwent ultrasound-guided transrectal biopsy. PDGF-BB was detected in the urine by enzyme-linked immunosorbent assay.
RESULTS: Patients with PCa had greater levels of prostate specific antigen and PDGF-BB. Receiver operating characteristic curve analysis showed that the optimal cut-of of PDGF-BB for the prediction of PCa was 1,504.9 with a sensitivity of 60% and a specificity of 51.3%. For a 100 unit increase in PDGF-BB, the likelihood for PCa increased about 4%.
CONCLUSION: PDGF-BB showed a significant predictive ability for PCa. Detection of PDGF-BB in urine with Elisa was easy and improved our diagnostic accuracy in the diagnosis of PCa.

Entities:  

Keywords:  Platelet-derived growth factor-BB; Prostate cancer; Prostate cancer biomarkers; Urine biomarkers

Year:  2018        PMID: 30374275      PMCID: PMC6198783          DOI: 10.1159/000447225

Source DB:  PubMed          Journal:  Curr Urol        ISSN: 1661-7649


  15 in total

1.  Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer.

Authors:  Abdo J Najy; Joshua J Won; Lisa S Movilla; Hyeong-Reh C Kim
Journal:  Mol Cancer Res       Date:  2012-06-11       Impact factor: 5.852

2.  APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer.

Authors:  Jack Groskopf; Sheila M J Aubin; Ina Lim Deras; Amy Blase; Sharon Bodrug; Craig Clark; Steven Brentano; Jeannette Mathis; Jimmykim Pham; Troels Meyer; Michelle Cass; Petrea Hodge; Maria Luz Macairan; Leonard S Marks; Harry Rittenhouse
Journal:  Clin Chem       Date:  2006-04-20       Impact factor: 8.327

Review 3.  Clinical use of novel urine and blood based prostate cancer biomarkers: a review.

Authors:  S Dijkstra; P F A Mulders; J A Schalken
Journal:  Clin Biochem       Date:  2013-10-29       Impact factor: 3.281

4.  Platelet-derived growth factor-BB accelerates prostate cancer growth by promoting the proliferation of mesenchymal stem cells.

Authors:  Jiwen Cheng; Huama Ye; Zhiyong Liu; Chuanliang Xu; Zhensheng Zhang; Yan Liu; Yinghao Sun
Journal:  J Cell Biochem       Date:  2013-07       Impact factor: 4.429

Review 5.  Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review.

Authors:  Andrew S Levey; Cassandra Becker; Lesley A Inker
Journal:  JAMA       Date:  2015-02-24       Impact factor: 56.272

Review 6.  Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values.

Authors:  A Semjonow; B Brandt; F Oberpenning; S Roth; L Hertle
Journal:  Prostate Suppl       Date:  1996

7.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

Review 8.  Biomarkers in prostate cancer surveillance and screening: past, present, and future.

Authors:  K Clint Cary; Mathew R Cooperberg
Journal:  Ther Adv Urol       Date:  2013-12

Review 9.  The role of proteomics in prostate cancer research: biomarker discovery and validation.

Authors:  Elisa Pin; Claudia Fredolini; Emanuel F Petricoin
Journal:  Clin Biochem       Date:  2012-12-22       Impact factor: 3.281

10.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Authors:  Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  1 in total

1.  Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer?

Authors:  Bum Sik Tae; Byeong Jo Jeon; Young Hoon Lee; Hoon Choi; Jae Young Park; Jae Hyun Bae
Journal:  Int Braz J Urol       Date:  2020 Mar-Apr       Impact factor: 1.541

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.